Viridian Therapeutics: Strategic Positioning and First-Mover Advantage in the TED Market
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...
Positive Outlook for Viridian Therapeutics: Analyst Reaffirms Buy Rating on Strong Competitive Position and Efficacy of VRDN-001
In a report released today, Serge Belanger from Needham maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report), with a price ...
Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) have received a consensus recommendation of “Moderate ...
Benzinga.com25d
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
10 analysts have expressed a variety of opinions on Viridian Therapeutics VRDN over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes ...
ETF Daily News16d
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 3.4% – Here’s Why
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) were down 3.4% during trading on Tuesday . The stock traded as low as $18.77 and last traded at $19.01. Approximately 81,134 ...
bovnews8d
Viridian Therapeutics Inc (VRDN) Stock Sees Market Value Hit $1.57 billion: What Are the Implications?
Wells Fargo has recently reduced Viridian Therapeutics Inc (VRDN) stock to Equal Weight rating, as announced on December 19, 2024, according to Finviz. Earlier, on November 25, 2024, TD Cowen had ...